A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 30 LOAD susceptibility loci2-12 are known, and risk is significantly polygenic13.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“Recent sequencing studies identified a number of genes that have rare variants associated with AD9-11,18-24.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“The NH2-terminal APP A673T(Icelandic) mutation, however, makes APP a less favorable substrate for 𝛃 -secretase, resulting in decreased A 𝛃 production (299).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [299]
In the citing paper
“This observation is also true for the rare variant p.A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against age-related cognitive decline as well as AD [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
In the citing paper
“The p.A673T variant was observed in control subjects aged over 85 years at a frequency of 0.45%, which is higher than that seen in AD patients [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
A new multipoint method for genome-wide association studies by imputation of genotypes
Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007) · Nature Genetics · doi:10.1038/ng2088 · Cited by 2,609
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
MDS Cognitive Performance Scale(C)
Morris, J. N., Fries, B. E., Mehr, D. R., Hawes, C., Phillips, C., Mor, V., & Lipsitz, L. A. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.4.m174 · Cited by 1,810
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cited by
Items 401–500 of 1,008
Panoutsopoulou, K., Hatzikotoulas, K., Xifara, D. K., Colonna, V., Farmaki, A.-E., Ritchie, G. R. S., Southam, L., Gilly, A., Tachmazidou, I., Fatumo, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms6345 · Cited by 70
Updating the Cognitive Performance Scale
Morris, J. N., Howard, E., Steel, K., Perlman, C. M., Fries, B. E., Garms-Homolová, V., Henrard, J., Hirdes, J. P., Ljunggren, G., Gray, L., et al. (2015) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988715598231 · Cited by 88
“These changes are responsive to prior criticisms that focused on the limited sensitivity of CPS.”
MethodInfluentialBrain biometals and Alzheimer's disease – boon or bane?
Prakash, A., Dhaliwal, G. K., Kumar, P., & Majeed, A. B. A. (2017) · International Journal of Neuroscience · doi:10.3109/00207454.2016.1174118 · Cited by 71
“AD is a neurodegenerative, dementia-inducing disorder of the elderly that has been estimated to affect more than 4 million people in the United States alone [2].”
BackgroundDecourt, B., D’Souza, G. X., Shi, J., Ritter, A., Suazo, J., & Sabbagh, M. N. (2022) · Aging and disease · doi:10.14336/ad.2021.0529 · Cited by 69
“For instance, the Iceland mutation on the amyloid precursor protein (APP) at position 673 (A673T) was shown to decrease the incidence of AD in carriers of this variant [2].”
BackgroundABCA7 rare variants and Alzheimer disease risk
Le Guennec, K., Nicolas, G., Quenez, O., Charbonnier, C., Wallon, D., Bellenguez, C., Grenier-Boley, B., Rousseau, S., Richard, A.-C., Rovelet-Lecrux, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002627 · Cited by 69
Nutrition and ageing: knowledge, gaps and research priorities
Mathers, J. C. (2013) · Proceedings of The Nutrition Society · doi:10.1017/s0029665112003023 · Cited by 86
“have shown that the A673T SNP in the APP gene that encodes the amyloid-b precursor protein appears to protect against AD((41)).”
Mikulca, J. A., Nguyen, V., Gajdosik, D. A., Teklu, S. G., Giunta, E. A., Lessa, E. A., Tran, C. H., Terak, E. C., & Raffa, R. B. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12112 · Cited by 69
“Recently, a coding mutation (A673T) in the APP gene has recently been identified that protects against Alzheimer disease.(5) This substitution is adjacent to the aspartyl protease b-site in APP and results in reduction in the formation of amyloidogenic peptides in vitro.”
BackgroundChalatsa, I., Arvanitis, D. A., Koulakiotis, N. S., Giagini, A. T., Skaltsounis, A., Papadopoulou‐Daifoti, Z., Tsarbopoulos, A., & Sanoudou, D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00249 · Cited by 71
“The treatment of neuronally differentiated SH-SY5Y-APP cells with trans-crocin 4 showed a significant decrease in BACE1, which represents a validated target for AD therapy due to its distinctive role in its pathogenesis (Jonsson et al., 2012).”
BackgroundLowering of Amyloid-Beta by β-Secretase Inhibitors — Some Informative Failures
Knopman, D. S. (2019) · New England Journal of Medicine · doi:10.1056/nejme1903193 · Cited by 69
Molecular and cellular aspects of age-related cognitive decline and Alzheimer’s disease
Hullinger, R., & Puglielli, L. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.008 · Cited by 68
BACE1: A Key Regulator in Alzheimer’s Disease Progression and Current Development of its Inhibitors
Patel, S., Bansoad, A. V., Singh, R., & Khatik, G. L. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211201094031 · Cited by 71
“Most carriers contain one copy of the A673T mutation, leading to a 20% reduction in Aβ production, which protects against AD [21-23].”
Disease variants in genomes of 44 centenarians
Freudenberg‐Hua, Y., Freudenberg, J., Vacic, V., Abhyankar, A., Emde, A., Ben‐Avraham, D., Barzilai, N., Oschwald, D., Christen, E., Koppel, J., et al. (2014) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.86 · Cited by 67
“Neither this centenarian nor any other subject in our study carried the protective variant A673T in the APP gene (Jonsson et al. 2012).”
BackgroundKretner, B., Trambauer, J., Fukumori, A., Mielke, J., Kuhn, P., Kremmer, E., Giese, A., Lichtenthaler, S. F., Haass, C., Arzberger, T., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505952 · Cited by 72
“The presenilin hypothesis can also not sufficiently explain APP FAD mutations and is inconsistent with a protective APP mutation in the Icelandic population, which reduces the risk for AD by reducing total A b levels (Jonsson et al , 2012).”
Blanco‐Gómez, A., Castillo‐Lluva, S., Sáez‐Freire, M. D. M., Hontecillas‐Prieto, L., Mao, J., Castellanos‐Martín, A., & Pérez‐Losada, J. (2016) · BioEssays · doi:10.1002/bies.201600084 · Cited by 82
Modulation of γ- and β-secretases as early prevention against Alzheimer's disease
Voytyuk, I., De Strooper, B., & Chávez-Gutiérrez, L. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.001 · Cited by 67
“This mutation resides adjacent to the β-cleavage site in APP and results in a 40% reduction of Aβ generation in vitro (72).”
Nguyen, P. H., Tarus, B., & Derreumaux, P. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp4115404 · Cited by 73
Regulation of neuronal autophagy and the implications in neurodegenerative diseases
Cai, Q., & Ganesan, D. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105582 · Cited by 75
“The increase in amyloidogenic processing of amyloid precursor protein (APP), which leads to Aβ overproduction, is a key feature underlying the pathogenesis of AD (Haass et al., 2007; 99. Hardy and Selkoe, 2002; Jonsson et al., 2012].”
BackgroundGenetics of Alzheimer's Disease
Kim, J. H. (2018) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2018.17.4.131 · Cited by 66
Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story
Stamford, A. W., & Strickland, C. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.04.016 · Cited by 74
Sassi, C., Guerreiro, R., Gibbs, R., Ding, J., Lupton, M. K., Troakes, C., Al-Sarraj, S., Niblock, M., Gallo, J.-M., Adnan, J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.002 · Cited by 65
Coskuner‐Weber, O., & Uversky, V. N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020336 · Cited by 75
“Another striking result (same residue) came from the analysis of APP in a set of whole-genome sequence data from 1795 Icelanders that resulted in the discovery that the A2T mutation is able to protect against AD in both heterozygous and homozygous carriers [106].”
ResultQing, H., Li, N.-M., Liu, K.-F., Qiu, Y.-J., Zhang, H.-H., & Nakanishi, H. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.247469 · Cited by 66
“Among them, the A673T mutation is the only one that protects against AD (Jonsson et al., 2012; Kokawa et al., 2015; Martiskainen et al., 2017; Lehtonen et al., 2018).”
BackgroundPresenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity
Barthet, G., Jordà-Siquier, T., Rumi-Masante, J., Bernadou, F., Müller, U., & Mulle, C. (2018) · Nature Communications · doi:10.1038/s41467-018-06813-x · Cited by 69
Alzheimer’s disease: where next for anti-amyloid therapies?
Hardy, J., & De Strooper, B. (2017) · Brain · doi:10.1093/brain/awx059 · Cited by 67
A mechanistic survey of Alzheimer's disease
Tang, Y., Zhang, D., Gong, X., & Zheng, J. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106735 · Cited by 70
Broadstock, M., Ballard, C., & Corbett, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.936848 · Cited by 58
“Additional support for this idea comes from inherited forms of AD, where mutations have been found within APP leading to autosomal-dominant forms of this disease and from the protective effects of an Icelandic mutation (A673T), which leads to a reduction in Ab formation [4].”
BackgroundWalsh, K. P., Minamide, L. S., Kane, S. J., Shaw, A. E., Brown, D. R., Pulford, B., Zabel, M. D., Lambeth, J. D., Kuhn, T. B., & Bamburg, J. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095995 · Cited by 64
“Results from several recent studies suggest that Ab plays an important role in development of cognitive impairment associated with aging and AD [47,48].”
Prion-like mechanisms in Alzheimer disease
Walker, L. C. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63945-5.00016-7 · Cited by 76
“, 2014) of Aβ, thereby lowering the risk of AD (Jonsson et al., 2012).”
BackgroundGenetics of Alzheimer’s disease: An East Asian perspective
Miyashita, A., Kikuchi, M., Hara, N., & Ikeuchi, T. (2023) · Journal of Human Genetics · doi:10.1038/s10038-022-01050-z · Cited by 64
“A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against agerelated cognitive decline as well as AD [43].”
BackgroundDecreased plasma β‐amyloid in the Alzheimer's disease APP A 673 Tvariant carriers
Martiskainen, H., Herukka, S., Stančáková, A., Paananen, J., Soininen, H., Kuusisto, J., Laakso, M., & Hiltunen, M. (2017) · Annals of Neurology · doi:10.1002/ana.24969 · Cited by 64
“Rare variants in APP and ABCA7 have been suggested to affect the risk of AD, potentially by modulating the levels of Ab.(3,4) To investigate the effects of these variants on Ab levels and cardiovascular and metabolic health, we identified carriers of APP A673T and ABCA7 rs200538373 C-allele in the Finnish METSIM cohor…”
BackgroundResultInfluentialVolmar, C.-H., Salah-Uddin, H., Janczura, K. J., Halley, P., Lambert, G., Wodrich, A., Manoah, S., Patel, N. H., Sartor, G. C., Mehta, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707544114 · Cited by 64
Dineen, T. A., Chen, K., Cheng, A. C., Derakhchan, K., Epstein, O. I., Esmay, J. D., Hickman, D., Kreiman, C. E., Marx, I. E., Wahl, R. C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5012676 · Cited by 66
Liebsch, F., Kulic, L., Teunissen, C., Shobo, A., Ulku, I., Engelschalt, V., Hancock, M. A., van der Flier, W. M., Kunach, P., Rosa-Neto, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10152-w · Cited by 68
Intracellular Trafficking Mechanisms of Synaptic Dysfunction in Alzheimer’s Disease
Perdigão, C., Barata, M. A., Araújo, M. N., Mirfakhar, F. S., Castanheira, J., & Guimas Almeida, C. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00072 · Cited by 65
Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat
Albright, C. F., Dockens, R. C., Meredith, J. E., Olson, R. E., Slemmon, R., Lentz, K. A., Wang, J.-S., Denton, R., Pilcher, G. D., Rhyne, P., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.199356 · Cited by 71
“was shown to have a protective effect against AD and cognitive impairment while causing a 40% decrease in Ab formation (Jonsson et al., 2012).”
BackgroundInfluentialPET imaging of tau protein targets: a methodology perspective
Lois, C., Gonzalez, I., Johnson, K. A., & Price, J. C. (2019) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9847-7 · Cited by 62
Mutated ATP10B increases Parkinson’s disease risk by compromising lysosomal glucosylceramide export
Martin, S., Smolders, S., den Haute, C. V., Heeman, B., van Veen, S., Crosiers, D., Beletchi, I., Verstraeten, A., Gossye, H., Gelders, G., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02145-7 · Cited by 70
Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease
Oyarzún, M. P., Tapia-Arellano, A., Cabrera, P., Jara-Guajardo, P., & Kogan, M. J. (2021) · Sensors · doi:10.3390/s21062067 · Cited by 65
“Also, gene mutations have been associated that cause autosomal dominant familial AD are APP on chromosome 21, presenilin-1 (PSEN1) on chromosome 14, and presenilin-2 (PSEN2) on chromosome 1 [35].”
BackgroundDel Prete, D., Lombino, F., Liu, X., & D'Adamio, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108576 · Cited by 66
“In fact, a polymorphism in APP that reduces APP processing by BACE1 protects humans from sporadic AD and normal aging-dependent cognitive decline [60].”
BackgroundWang, Q., Xiao, B., Cui, S., Song, H., Qian, Y., Dong, L., An, H., Cui, Y., Zhang, W., He, Y., et al. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.018218 · Cited by 68
“The A673T mutation impairs BACE1-mediated cleavage of APP and is therefore protective against AD (Jonsson et al., 2012).”
BackgroundWoodling, N. S., & Andreasson, K. I. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00016 · Cited by 63
Sakamoto, K., Matsuki, S., Matsuguma, K., Yoshihara, T., Uchida, N., Azuma, F., Russell, M., Hughes, G., Haeberlein, S. B., Alexander, R. C., et al. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.950 · Cited by 61
RAB10: an Alzheimer’s disease resilience locus and potential drug target
Tavana, J., Rosene, M., Jensen, N., Ridge, P. G., Kauwe, J. S. K., & Karch, C. M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159148 · Cited by 62
“Those with the strongest protective effect include APOE ε2 and APP-A673T.(34,35) Thus, genes and pathways involved in increasing AD risk may also confer resilience to disease.”
Rare TREM2 variants associated with Alzheimer’s disease display reduced cell surface expression
Sirkis, D. W., Bonham, L. W., Aparicio, R. E., Geier, E. G., Ramos, E. M., Wang, Q., Karydas, A., Miller, Z. A., Miller, B. L., Coppola, G., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0367-7 · Cited by 61
“Rare variants that confer both risk for [1–5] and protection from [6, 7] different forms of neurodegeneration have been identified, but, due to their low MAF, most of these studies required very large cohorts to confirm the effect of these single variants on disease.”
BackgroundFindeis, M. A., Schroeder, F. C., McKee, T. D., Yager, D., Fraering, P. C., Creaser, S. P., Austin, W., Clardy, J., Wang, R., Selkoe, D. J., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000857 · Cited by 64
Li, J., Wen, P., Li, W., & Zhou, J. (2015) · Neuroreport · doi:10.1097/wnr.0000000000000419 · Cited by 61
Timmers, M., Van Broeck, B., Ramael, S., Slemmon, J., De Waepenaert, K., Russu, A., Bogert, J., Stieltjes, H., Shaw, L. M., Engelborghs, S., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.08.001 · Cited by 60
Genetics of Alzheimer’s disease: From pathogenesis to clinical usage
Shao, W., Peng, D., & Wang, X. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.074 · Cited by 80
“Although the identification of these variants seems a tough task, advances in sequencing technology make this possible, such as whole-exome sequencing (WES) and whole-genome sequencing (WGS).”
BackgroundInfluentialZhao, Y., Zhao, R., Wu, J., Wang, Q., Pang, K., Shi, Q., Gao, Q., Hu, Y., Dong, X., Zhang, J., et al. (2018) · BioFactors · doi:10.1002/biof.1411 · Cited by 55
“Ab oligomers, a death-promoting peptide, play a central role in inducing synaptic toxicity associated with synaptic dysfunction and neuronal death both in vivo and in vitro [6,8,35,36].”
Si, G., & Álvarez, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21722 · Cited by 65
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi-Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 59
Lista, S., Dubois, B., & Hampel, H. J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0515-3 · Cited by 66
“In particular, an A673T substitution within the amyloid-β precursor protein (APP) gene has been shown to be protective against cognitive decline in the elderly without AD (51).”
Hunt, K. W., Cook, A. W., Watts, R. J., Clark, C. T., Vigers, G. P. A., Smith, D. J., Metcalf, A. T., Gunawardana, I. W. K., Burkard, M., Cox, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4002154 · Cited by 63
Self-citationBACE1 as a Therapeutic Target in Alzheimer’s Disease: Rationale and Current Status
Evin, G. M., & Hince, C. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0099-3 · Cited by 65
“As the non-amyloidogenic pathway does not produce Ab, a preference for the amyloidogenic over the nonamyloidogenic APP processing pathway predisposes AD pathology, as illustrated by the recent discovery of a mutation in the APP gene, in Finnish families, that impairs b-secretase cleavage, lessens Ab production, and ap…”
BackgroundIncreased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
Mattsson, N., Insel, P. S., Palmqvist, S., Stomrud, E., van Westen, D., Minthon, L., Zetterberg, H., Blennow, K., & Hansson, O. (2016) · Nature Communications · doi:10.1038/ncomms10918 · Cited by 59
An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice
Cheng, Y.-S., Chen, Z.-T., Liao, T., Lin, C. W., Shen, H. C.-H., Wang, Y., Chang, C., Liu, R., Chen, R. P. ‐., & Tu, P. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606666 · Cited by 63
“Although the etiology of AD remains unclear, the amyloid cascade hypothesis is the most supported explanation to date and is recently further strengthened by the finding of a protective APP mutation near the b -cleavage site against the development of late-onset dementia (Jonsson et al , 2012).”
Neuritic Plaques — Gateways to Understanding Alzheimer’s Disease
Tsering, W., & Prokop, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-023-03736-7 · Cited by 59
“Interestingly, an APP missense mutation (A673T) has been described that decreases APP cleavage by β-secretase and lowers the risk of AD and cognitive decline [6] further supporting the critical role of APP-cleavage in AD pathophysiology.”
Backgroundvan Leeuwen, E. M., Karssen, L. C., Deelen, J., Isaacs, A., Medina-Gomez, C., Mbarek, H., Kanterakis, A., Trompet, S., Postmus, I., Verweij, N., et al. (2015) · Nature Communications · doi:10.1038/ncomms7065 · Cited by 60
Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases
Walker, L. C. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-120215-034943 · Cited by 63
“Remarkably, a rare genetic variant in the APP gene that causes an amino acid substitution at position 2 of Aβ (A673T, according to APP770 numbering) reduces the production (67) and aggregation propensity (8) of Aβ, and also lowers the risk of developing AD (67).”
BackgroundThe Role of Microglia in Prion Diseases: A Paradigm of Functional Diversity
Obst, J., Simon, E., Mancuso, R., & Gómez‐Nicola, D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00207 · Cited by 63
“TREM2 has been implicated in several neurodegenerative diseases such as AD (Jonsson et al., 2012; Guerreiro R. J. et al., 2013), frontotemporal dementia (Guerreiro R. et al., 2013) and ALS (Cady et al., 2014).”
BackgroundNaushad, M., Durairajan, S. S. K., Bera, A. K., Senapati, S., & Li, M. (2019) · Planta Medica · doi:10.1055/a-1019-9819 · Cited by 62
Central and peripheral circadian clocks and their role in Alzheimer's disease
Chauhan, R., Chen, K.-F., Kent, B. A., & Crowther, D. C. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030627 · Cited by 58
“…in familial AD (Goate et al., 1991; Rogaev et al., 1995; Sherrington et al., 1995) and wholegenome studies of the more common, sporadic form of AD (Jonsson et al., 2012) indicate that the increased production of aggregationprone Aβ peptides, the main component of plaques (Glenner and Wong, 1984;…”
BackgroundZheng, X., Liu, D., Roychaudhuri, R., Teplow, D. B., & Bowers, M. T. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00171 · Cited by 62
Lumsden, A. L., Rogers, J. T., Majd, S., Newman, M., Sutherland, G. T., Verdile, G., & Lardelli, M. T. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00533 · Cited by 63
Clinical Genetics of Alzheimer’s Disease
Zou, Z., Liu, C., Che, C., & Huang, H. (2014) · BioMed Research International · doi:10.1155/2014/291862 · Cited by 71
“The amyloid hypothesis is further supported by the opposite situation, in which an APP mutation reducing the amount of amyloid formation in fact protects against AD [49].”
Dubal, D. B., Broestl, L., & Worden, K. (2012) · Biology of Sex Differences · doi:10.1186/2042-6410-3-24 · Cited by 55
“For example, models that express hAPP via targeted insertion and from the gene’s own promoter might produce more physiological results.”
BackgroundInfluentialReview: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease
Ameen‐Ali, K. E., Wharton, S. B., Simpson, J. E., Heath, P. R., Sharp, P., & Berwick, J. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12440 · Cited by 60
Estrada, M., Herrera‐Arozamena, C., Pérez, C., Viña, D., Romero, A., Morales-Garcia, J. A., Pérez‐Castillo, A., & Rodríguez-Franco, M. I. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.055 · Cited by 61
Rare Functional Variant in TM2D3 is Associated with Late-Onset Alzheimer's Disease
Jakobsdottir, J., van der Lee, S. J., Bis, J. C., Chouraki, V., Li-Kroeger, D., Yamamoto, S., Grove, M. L., Naj, A., Vronskaya, M., Salazar, J. L., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006327 · Cited by 58
“Recent examples include a rare protective allele of APP [16] as well as variants in the novel genes TREM2 .”
BackgroundBlood cell-produced amyloid-β induces cerebral Alzheimer-type pathologies and behavioral deficits
Sun, H.-L., Chen, S.-H., Yu, Z.-Y., Cheng, Y., Tian, D.-Y., Fan, D.-Y., He, C.-Y., Wang, J., Sun, P.-Y., Chen, Y., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0842-1 · Cited by 56
Chen, J., Yin, B., Wang, W., & Sun, H. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00234 · Cited by 59
Koriyama, Y., Hori, A., Ito, H., Yonezawa, S., Baba, Y., Tánimoto, N., Ueno, T., Yamamoto, S., Yamamoto, T., Asada, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01917 · Cited by 62
Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer’s Disease
Nadeem, M. S., Hosawi, S. B. I., Alshehri, S., Ghoneim, M. M., Imam, S. S., Murtaza, B. N., & Kazmi, I. A. (2021) · Biomolecules · doi:10.3390/biom11111635 · Cited by 63
ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease
Letronne, F., Laumet, G., Ayral, A.-M., Chapuis, J., Demiautte, F., Laga, M., Vandenberghe, M. E., Malmanche, N., Leroux, F., Eysert, F., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.06.002 · Cited by 58
“…o,p, David Tulasne k, Claudine Berr q, Jean-Jacques Hauw r, Yves Lemoine b,c,l, Philippe Amouyel a,b,c,p, David Mann s, Rebecca Déprez b,c,h, Frédéric Checler i,j, David Hot b,c,l, Thierry Delzescaux f,g, Kris Gevaert d,e, Jean-Charles Lambert a,b,c,⁎ a INSERM, U1167, Laboratoire d'Excellence…”
BackgroundInfluentialEpigenetic and genetic components of height regulation
Benonisdottir, S., Oddsson, A., Helgason, A., Kristjansson, R. P., Sveinbjornsson, G., Oskarsdottir, A., Thorleifsson, G., Davidsson, O. B., Arnadottir, G. A., Sulem, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms13490 · Cited by 58
Self-citationCortés, A., Dendrou, C. A., Motyer, A., Jostins, L., Vukcevic, D., Dilthey, A., Donnelly, P., Leslie, S., Fugger, L. H., & McVean, G. (2017) · Nature Genetics · doi:10.1038/ng.3926 · Cited by 63
Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models
Cenini, G., Hebisch, M., Iefremova, V., Flitsch, L. J., Breitkreuz, Y., Tanzi, R. E., Kim, D. Y., Peitz, M., & Brüstle, O. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103568 · Cited by 56
Eysert, F., Coulon, A., Boscher, E., Vreulx, A.-C., Flaig, A., Mendes, T., Hughes, S., Grenier-Boley, B., Hanoulle, X., Demiautte, F., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00926-w · Cited by 55
Tang, L., Liu, L., Li, G., Jiang, P., Wang, Y., & Li, J. (2019) · BioMed Research International · doi:10.1155/2019/9642589 · Cited by 79
“The transgenic model studies have mainly focused on several special genes including APP, PS1/2 [28, 29], and Tau [30].”
BackgroundMetabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 62
Genetics and Underlying Pathology of Dementia
Ferencz, B., & Gerritsen, L. (2015) · Neuropsychology Review · doi:10.1007/s11065-014-9276-3 · Cited by 73
“Recently, a GWA study among Icelandic people showed that a rare mutation in the APP gene decreases the risk for dementia and AD in particular (Jonsson et al. 2012).”
BackgroundThe Normal and Pathologic Roles of the Alzheimer's β-secretase, BACE1
Kandalepas, P., & Vassar, R. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140604122059 · Cited by 54
Caspase‐6 as a novel early target in the treatment of Alzheimer's disease
LeBlanc, A. C. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12250 · Cited by 61
Das, P., Murray, B., & Belfort, G. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2014.12.013 · Cited by 58
“Recently, a rare A2T variant was found to protect against AD and cognitive decline in the elderly without AD (40).”
BackgroundEffect of Presenilin Mutations on APP Cleavage; Insights into the Pathogenesis of FAD
Li, N., Liu, K., Qiu, Y., Ren, Z., Dai, R., Deng, Y., & Qing, H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00051 · Cited by 54
“Frontiers in Aging Neuroscience | www.frontiersin.org 1 March 2016 | Volume 8 | Article 51 with preference for positions 40 and 42, forming the Aβ1−40 and Aβ1−42 peptides (Jonsson et al., 2012).”
BackgroundABCA7 p.G215S as potential protective factor for Alzheimer's disease
Sassi, C., Nalls, M. A., Ridge, P. G., Gibbs, J. R., Ding, J., Lupton, M. K., Troakes, C., Lunnon, K., Al-Sarraj, S., Brown, K. S., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.004 · Cited by 54
“A673T (MAF 7x10e -4 in our cohort and MAF 5x10e -4 among the European non-finnish, ExAC database, released 13 January 2015)(Jonsson et al., 2012)”
BackgroundFunctions of the Alzheimer’s Disease Protease BACE1 at the Synapse in the Central Nervous System
Munro, K. M., Nash, A., Pigoni, M., Lichtenthaler, S. F., & Gunnersen, J. M. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0800-1 · Cited by 62
AP ‐2 reduces amyloidogenesis by promoting BACE 1 trafficking and degradation in neurons
Bera, S., Camblor‐Perujo, S., Calleja Barca, E., Negrete‐Hurtado, A., Racho, J., De Bruyckere, E., Wittich, C., Ellrich, N., Martins, S., Adjaye, J., et al. (2020) · EMBO reports · doi:10.15252/embr.201947954 · Cited by 56
“It is well established that the increased amyloidogenic processing of amyloid precursor protein (APP), resulting in augmented production of either total amyloid-b (Ab) or a shift in the Ab1–40:Ab1–42 ratio toward formation of the more toxic Ab1–42, are key features underlying the pathogenesis of AD [2,3].”
γ-Secretase and its modulators: Twenty years and beyond
Xia, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.011 · Cited by 54
“Genetic studies show that detrimental familial ADlinked missense mutations in APP or PS increase the ratio of 42 residue of Aβ (Aβ42) to a more common 40-residue of Aβ (Aβ40) and cause early onset AD, while a beneficial mutation in APP leads to decreased Aβ production and those carriers maintain intact cognitive funct…”
BackgroundApplications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
Plano, L. M. D., Calabrese, G., Conoci, S., Guglielmino, S. P. P., Oddo, S., & Caccamo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158714 · Cited by 62
“While most of the known mutations in the APP gene are causative of the disease, some mutations/variations are protective against AD [47,48].”
BackgroundSystems biology of neurodegenerative diseases
Wood, L. B., Winslow, A. R., & Strasser, S. D. (2015) · Integrative Biology · doi:10.1039/c5ib00031a · Cited by 53
Octave, J., Pierrot, N., Ferao Santos, S., Nalivaeva, N. N., & Turner, A. J. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12239 · Cited by 54
“This mutation, adjacent to the b-secretase cleavage site, causes a significant shift in APP processing away from the amyloidogenic pathway and reduced Ab levels in a cell-based model (Jonsson et al. 2012).”
BackgroundJayne, T., Newman, M., Verdile, G., Sutherland, G. T., Münch, G. W., Musgrave, I., Nik, S. H. M., & Lardelli, M. T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151186 · Cited by 57
“of A PP by around 40% [159] can be seen in this”
BackgroundNeural stem/progenitor cells in Alzheimer's disease.
Tincer, G., Mashkaryan, V., Bhattarai, P., & Kızıl, Ç. (2016) · PubMed Central · Cited by 66
The Metalloprotease Meprin β Is an Alternative β-Secretase of APP
Becker-Pauly, C., & Pietrzik, C. U. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00159 · Cited by 52
“The recently described APP mutation A673T that has been shown to protect against AD as well as against cognitive decline in the elderly independent of AD was analyzed (Jonsson et al., 2012).”
BackgroundRare genetic variation in mitochondrial pathways influences the risk for Parkinson's disease
Gaare, J. J., Nido, G. S., Sztromwasser, P., Knappskog, P. M., Dahl, O., Lund‐Johansen, M., Maple‐Grødem, J., Alves, G. W., Tysnes, O., Johansson, S., et al. (2018) · Movement Disorders · doi:10.1002/mds.64 · Cited by 55
“Moreover, rare protective variants have been shown in other complex disorders including autoimmunity,(43) cancer,(44) ischemic vascular disease,(45) and Alzheimer’s disease.(46) The pathway of mitochondrial calcium homeostasis also reached nominal significance in both cohorts, but only survived multiple testing correc…”
BackgroundChen, G., Andrade-Talavera, Y., Tambaro, S., Leppert, A., Nilsson, H. E., Zhong, X., Landreh, M., Nilsson, P., Hebert, H., Biverstål, H., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0757-z · Cited by 61
Mechanisms of neurodegeneration — Insights from familial Alzheimer’s disease
Chávez-Gutiérrez, L., & Szaruga, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.03.005 · Cited by 58
An Early Folding Contact between Phe19 and Leu34 is Critical for Amyloid-β Oligomer Toxicity
Das, A. K., Rawat, A., Bhowmik, D., Pandit, R., Huster, D., & Maiti, S. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00074 · Cited by 56
Lacour, M., Quenez, O., Rovelet‐Lecrux, A., Salomon, B., Rousseau, S., Richard, A., Quillard‐Muraine, M., Pasquier, F., Rollin‐Sillaire, A., Martinaud, O., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190193 · Cited by 55
Metadata
- Authors
- Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., & Stefansson, K.
- Affiliations
- Genentech (US)
- deCODE Genetics (Iceland) (IS)
- University of Oslo (NO)
- Karolinska Institutet (SE)
- University of Helsinki (FI)
- ORCID
- Venue
- Nature
- Published
- 2012-07-11
- Volume
- 488
- Issue
- 7409
- Pages
- 96-99
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2154755614
- Cited by
- 1,738
- References
- 26
- Citations by year
- 2026: 56 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 70 · 2021: 120 · 2020: 134 · 2019: 107 · 2018: 134 · 2017: 145 · 2016: 155 · 2015: 166 · 2014: 173 · 2013: 154 · 2012: 60
- FWCI
- 119.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-102924, HL-102925, HL 103010, HL-102926)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, amyloid precursor protein, APP gene, protective genetic variants, cognitive decline in older adults, amyloid plaques, β-cleavage, amyloidogenic peptides, genetic risk, Icelandic population
- MeSH terms
- Aging, Alleles, Alzheimer Disease, Cognition, Cognition Disorders, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Amyloid Precursor Protein Secretases, HEK293 Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.